Neo-Advent Technologies, LLC (NAT) is a pre-clinical contract research organization offering a full spectrum of the CMC capabilities required for the successful advancement of the drug development programs. The core competencies include drug formulation and analysis. The company operates state-of-the art solid dose facility to support accelerated development of the tablet forms and coated formulations, from feasibility studies to production batches. NAT conducts due diligence and perform enabling studies for the programs focused on the new drug delivery approaches and drug reformulation.
This is the content in the alert Area Go